Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

BCMA: A new biomarker for multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.19
Views: 864

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

Dr James Berenson talks to ecancer at the International Myeloma Workshop 2019 about BCMA or B-cell maturation antigen.

This is a novel marker for multiple myeloma which will improve the speed at which changes in clinical status can be determined, and is also a good prognostic marker.

The benefits of this marker therefore allow patients to move quickly away from a regimen that isn't working, or begin with less treatment.

Dr Berenson predicts that we could establish a threshold for the amount of BCMA in a patient which provides an accurate level of risk for developing myeloma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation